Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|The Lancet|2019Cited by 581
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|Neuro-Oncology|2017Cited by 22
Which infrastructure can I use to share human neuroimaging data? A survey and literature review on current solutions for EU researchersJérémy Lefort‐Besnard, Camille Maumet, Ruben Emanuel Nechifor et al.|Aperture Neuro|2025Cited by 1
Which infrastructure can I use to share human neuroimaging data? Recommendations for EU researchers based on a survey and literature reviewJérémy Lefort‐Besnard, Camille Maumet, Alexandre Pron et al.|HAL (Le Centre pour la Communication Scientifique Directe)|2025Cited by 0
Which infrastructure can I use to share human neuroimaging data? A guide for researchers based in the EUJérémy Lefort‐Besnard, Camille Maumet, Alexandre Pron et al.|Ghent University Academic Bibliography (Ghent University)|2025Cited by 0